Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA001124-03
Application #
3079629
Study Section
(SRC)
Project Start
1987-02-01
Project End
1991-01-31
Budget Start
1989-02-01
Budget End
1990-01-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Louisville
Department
Type
Schools of Medicine
DUNS #
City
Louisville
State
KY
Country
United States
Zip Code
40292
Feldhoff, P W; Mirski, S E; Cole, S P et al. (1994) Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 54:756-62
Burden, D A; Sullivan, D M (1994) Phosphorylation of the alpha- and beta-isoforms of DNA topoisomerase II is qualitatively different in interphase and mitosis in Chinese hamster ovary cells. Biochemistry 33:14651-5
Kroll, D J; Sullivan, D M; Gutierrez-Hartmann, A et al. (1993) Modification of DNA topoisomerase II activity via direct interactions with the cyclic adenosine-3',5'-monophosphate response element-binding protein and related transcription factors. Mol Endocrinol 7:305-18
Sullivan, D M; Eskildsen, L A; Groom, K R et al. (1993) Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Mol Pharmacol 43:207-16
Burden, D A; Goldsmith, L J; Sullivan, D M (1993) Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II. Biochem J 293 ( Pt 1):297-304
Webb, C D; Latham, M D; Lock, R B et al. (1991) Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51:6543-9
Sullivan, D M; Latham, M D; Rowe, T C et al. (1989) Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28:5680-7
Ross, W E; Sullivan, D M; Chow, K C (1988) Altered function of DNA topoisomerases as a basis for antineoplastic drug action. Important Adv Oncol :65-81